Market Cap 6.73M
Revenue (ttm) 0.00
Net Income (ttm) -13.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 14,878
Avg Vol 78,354
Day's Range N/A - N/A
Shares Out 3.42M
Stochastic %K 44%
Beta 1.73
Analysts Strong Sell
Price Target $16.67

Company Profile

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005...

Industry: Biotechnology
Sector: Healthcare
Phone: 904 300 0701
Address:
822 A1A North, Suite 306, Ponte Vedra, United States
MikeTechnician
MikeTechnician Jul. 31 at 4:27 PM
$CVKD Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-launches-partnering-process-120000853.html
0 · Reply
WallStreetSignals
WallStreetSignals Jul. 29 at 1:22 PM
$CVKD Cadrenal Therapeutics (Nasdaq: #CVKD) announced a strategic realignment of its clinical portfolio and has officially launched a partnering process focused on its late-stage cardiac critical care assets. The initiative includes out-licensing, portfolio monetization, and co-development opportunities designed to accelerate commercialization. https://www.cadrenal.com/cadrenal-therapeutics-launches-partnering-process-as-its-cardiac-acute-critical-care-assets-advance-to-transaction-readiness-following-landmark-isth-data-presentation #CVKD #CadrenalTherapeutics #Nasdaq #Biotech #Biotechnology #Healthcare #Cardiology #CriticalCare #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #StrategicPartnership #Licensing #Commercialization #Innovation #GrowthStocks #StockMarket #Investing #TheBullRunShow
0 · Reply
Channelchek
Channelchek Jul. 23 at 1:57 PM
Noble Capital Markets Research Report: Cadrenal Therapeutics ($CVKD) – Strategic Changes Create A New Cardiac Acute Critical Care Franchise Advancing Products Through Partnerships. Cadrenal announced that it has modified its development strategy and product pipeline to focus on therapies for cardiac surgical care and orphan cardiac conditions. It now plans to advance the products through development partnerships, licensing, and commercialization agreements to minimize capital expenditures. Read full report here: https://www.channelchek.com/news-channel/cadrenal-therapeutics-cvkd-strategic-changes-create-a-new-cardiac-acute-critical-care-franchise
0 · Reply
kule04
kule04 Jul. 23 at 9:23 AM
$CVKD Did anyone do serious DD on this? The asymmetry looks insane here, especially with a good potential partner... How come the stock price is still getting crushed
1 · Reply
MikeTechnician
MikeTechnician Jul. 22 at 6:27 PM
$CVKD Dice rolling -
0 · Reply
WallStreetSignals
WallStreetSignals Jul. 22 at 6:14 PM
0 · Reply
WallStreetSignals
WallStreetSignals Jul. 22 at 6:14 PM
0 · Reply
WallStreetSignals
WallStreetSignals Jul. 22 at 6:14 PM
$CVKD 👑📈 #CVKD Cadrenal Therapeutics has launched a partnering process as its acute critical cardiac care assets reach transaction readiness after a landmark ISTH data presentation. https://www.globenewswire.com/news-release/2026/07/21/3330413/0/en/cadrenal-therapeutics-launches-partnering-process-as-its-cardiac-acute-critical-care-assets-advance-to-transaction-readiness-following-landmark-isth-data-presentation.html #TheBullRunShow #BullMarket #InvestSmart #Opportunities #Finance #Investing #BusinessGrowth #BullMarket #TrendingStocks #TopPennyStockInc
0 · Reply
MikeTechnician
MikeTechnician Jul. 22 at 2:47 PM
$CVKD #NASDAQ Cadrenal Therapeutics: A Paradigm Shift in HIT Treatment. https://www.youtube.com/watch?v=4UcqG2DwjEs
0 · Reply
MikeTechnician
MikeTechnician Jul. 22 at 1:17 PM
$CVKD " Cadrenal has assembled multiple late-stage critical care cardiovascular assets designed to address serious conditions for which existing treatment options remain inadequate. This capital-efficient operational model addresses a large, unserved therapeutic whitespace, unlocking substantial cumulative platform potential. The strategy positions Cadrenal's assets as high-value additions which may be capable of delivering immediate value to the pipelines of global companies across rare disease therapies, critical care cardiology, and cardiac intensive care unit (CICU) medical products.
0 · Reply
Latest News on CVKD
Cadrenal Therapeutics Proxy statement: Proxy filing

Jul 23, 2026, 8:00 AM EDT - 8 days ago

Cadrenal Therapeutics Proxy statement: Proxy filing


Cadrenal Therapeutics to initiate CAD-1005 trial

2026-06-15T13:15:54.000Z - 6 weeks ago

Cadrenal Therapeutics to initiate CAD-1005 trial


Cadrenal Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Cadrenal Therapeutics Quarterly report: Q1 2026


Cadrenal Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Cadrenal Therapeutics Earnings release: Q1 2026


Cadrenal Therapeutics Slides: Investor presentation

May 4, 2026, 7:00 AM EDT - 3 months ago

Cadrenal Therapeutics Slides: Investor presentation


Cadrenal Therapeutics Inc trading resumes

2026-04-01T19:35:16.000Z - 4 months ago

Cadrenal Therapeutics Inc trading resumes


Cadrenal Therapeutics Annual report: Q4 2025

Mar 31, 2026, 9:00 AM EDT - 4 months ago

Cadrenal Therapeutics Annual report: Q4 2025


Cadrenal Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 9:00 AM EDT - 4 months ago

Cadrenal Therapeutics Earnings release: Q4 2025


Cadrenal Therapeutics highlights research on 12-LOX inhibition

2026-03-12T12:21:38.000Z - 5 months ago

Cadrenal Therapeutics highlights research on 12-LOX inhibition


Cadrenal Therapeutics announces Phase 2 results for CAD-1005

2026-02-24T13:39:32.000Z - 5 months ago

Cadrenal Therapeutics announces Phase 2 results for CAD-1005


Cadrenal's Quiet Expansion Play Is Starting to Get Loud

Dec 12, 2025, 11:00 AM EST - 8 months ago

Cadrenal's Quiet Expansion Play Is Starting to Get Loud


Cadrenal Therapeutics Slides: Investor presentation

Dec 11, 2025, 7:00 AM EST - 8 months ago

Cadrenal Therapeutics Slides: Investor presentation


Cadrenal Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 9:00 AM EST - 9 months ago

Cadrenal Therapeutics Earnings release: Q3 2025


Cadrenal Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 9:00 AM EST - 9 months ago

Cadrenal Therapeutics Quarterly report: Q3 2025


Cadrenal Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Cadrenal Therapeutics Earnings release: Q2 2025


Cadrenal Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Cadrenal Therapeutics Quarterly report: Q2 2025


Cadrenal Therapeutics announces trial plans for tecarfarin

2025-08-05T10:25:11.000Z - 1 year ago

Cadrenal Therapeutics announces trial plans for tecarfarin


Cadrenal Therapeutics Proxy statement: Proxy Filing

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Proxy statement: Proxy Filing


Cadrenal Therapeutics Proxy statement: Proxy Filing

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Proxy statement: Proxy Filing


Cadrenal Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Cadrenal Therapeutics Earnings release: Q1 2025


Cadrenal Therapeutics Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Cadrenal Therapeutics Quarterly report: Q1 2025


Cadrenal Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Cadrenal Therapeutics Earnings release: Q4 2024


Cadrenal Therapeutics Annual report: Q4 2024

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Cadrenal Therapeutics Annual report: Q4 2024


Cadrenal Therapeutics  teams with Abbott inTECH-LVAD trial

2025-03-04T13:21:36.000Z - 1 year ago

Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial

ABT


Cadrenal Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Cadrenal Therapeutics Quarterly report: Q3 2024


MikeTechnician
MikeTechnician Jul. 31 at 4:27 PM
$CVKD Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-launches-partnering-process-120000853.html
0 · Reply
WallStreetSignals
WallStreetSignals Jul. 29 at 1:22 PM
$CVKD Cadrenal Therapeutics (Nasdaq: #CVKD) announced a strategic realignment of its clinical portfolio and has officially launched a partnering process focused on its late-stage cardiac critical care assets. The initiative includes out-licensing, portfolio monetization, and co-development opportunities designed to accelerate commercialization. https://www.cadrenal.com/cadrenal-therapeutics-launches-partnering-process-as-its-cardiac-acute-critical-care-assets-advance-to-transaction-readiness-following-landmark-isth-data-presentation #CVKD #CadrenalTherapeutics #Nasdaq #Biotech #Biotechnology #Healthcare #Cardiology #CriticalCare #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #StrategicPartnership #Licensing #Commercialization #Innovation #GrowthStocks #StockMarket #Investing #TheBullRunShow
0 · Reply
Channelchek
Channelchek Jul. 23 at 1:57 PM
Noble Capital Markets Research Report: Cadrenal Therapeutics ($CVKD) – Strategic Changes Create A New Cardiac Acute Critical Care Franchise Advancing Products Through Partnerships. Cadrenal announced that it has modified its development strategy and product pipeline to focus on therapies for cardiac surgical care and orphan cardiac conditions. It now plans to advance the products through development partnerships, licensing, and commercialization agreements to minimize capital expenditures. Read full report here: https://www.channelchek.com/news-channel/cadrenal-therapeutics-cvkd-strategic-changes-create-a-new-cardiac-acute-critical-care-franchise
0 · Reply
kule04
kule04 Jul. 23 at 9:23 AM
$CVKD Did anyone do serious DD on this? The asymmetry looks insane here, especially with a good potential partner... How come the stock price is still getting crushed
1 · Reply
MikeTechnician
MikeTechnician Jul. 22 at 6:27 PM
$CVKD Dice rolling -
0 · Reply
WallStreetSignals
WallStreetSignals Jul. 22 at 6:14 PM
0 · Reply
WallStreetSignals
WallStreetSignals Jul. 22 at 6:14 PM
0 · Reply
WallStreetSignals
WallStreetSignals Jul. 22 at 6:14 PM
$CVKD 👑📈 #CVKD Cadrenal Therapeutics has launched a partnering process as its acute critical cardiac care assets reach transaction readiness after a landmark ISTH data presentation. https://www.globenewswire.com/news-release/2026/07/21/3330413/0/en/cadrenal-therapeutics-launches-partnering-process-as-its-cardiac-acute-critical-care-assets-advance-to-transaction-readiness-following-landmark-isth-data-presentation.html #TheBullRunShow #BullMarket #InvestSmart #Opportunities #Finance #Investing #BusinessGrowth #BullMarket #TrendingStocks #TopPennyStockInc
0 · Reply
MikeTechnician
MikeTechnician Jul. 22 at 2:47 PM
$CVKD #NASDAQ Cadrenal Therapeutics: A Paradigm Shift in HIT Treatment. https://www.youtube.com/watch?v=4UcqG2DwjEs
0 · Reply
MikeTechnician
MikeTechnician Jul. 22 at 1:17 PM
$CVKD " Cadrenal has assembled multiple late-stage critical care cardiovascular assets designed to address serious conditions for which existing treatment options remain inadequate. This capital-efficient operational model addresses a large, unserved therapeutic whitespace, unlocking substantial cumulative platform potential. The strategy positions Cadrenal's assets as high-value additions which may be capable of delivering immediate value to the pipelines of global companies across rare disease therapies, critical care cardiology, and cardiac intensive care unit (CICU) medical products.
0 · Reply
MikeTechnician
MikeTechnician Jul. 22 at 11:32 AM
$CVKD Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-launches-partnering-process-as-its-cardiac-9t32kq341jho.html
0 · Reply
prusio1
prusio1 Jul. 21 at 3:56 PM
$CVKD CVKD's cash position remains relatively modest. The company reported $2.3 million in cash as of March 31, 2026, and subsequently completed a $2.5 million financing on April 1, 2026. Management also stated it continues to evaluate additional financing alternatives to support its planned Phase 3 program. If no partnership materializes and cash continues to decline, a new financing would become more likely. The company could still: -establish a new ATM facility, -conduct a registered direct offering, -pursue a private placement,
1 · Reply
WallStreetSignals
WallStreetSignals Jul. 21 at 1:40 PM
$CVKD #News | Cadrenal Therapeutics, Inc. (Nasdaq: #CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. Concurrently, the Company has initiated a structured process to secure strategic out-licensing, portfolio monetization, or commercial co-development partnerships for its late-stage assets. https://www.globenewswire.com/news-release/2026/07/21/3330413/0/en/Cadrenal-Therapeutics-Launches-Partnering-Process-as-Its-Cardiac-Acute-Critical-Care-Assets-Advance-to-Transaction-Readiness-Following-Landmark-ISTH-Data-Presentation.html
0 · Reply
MikeTechnician
MikeTechnician Jul. 21 at 1:24 PM
$CVKD - Story Highlights Cadrenal reorganized its late-stage cardiovascular portfolio into a Cardiac Acute Critical Care Franchise to target severe, underserved cardiac patients. On July 21, 2026, the company launched a partnering process after strong CAD-1005 data, seeking deals to monetize and co-develop its key assets. I baby 😂
0 · Reply
focafoca99
focafoca99 Jul. 21 at 1:09 PM
$CVKD realigned its portfolio into a Cardiac Acute Care franchise, launching a process to seek out-licensing and co-development deals.
0 · Reply
topstockalerts
topstockalerts Jul. 17 at 10:57 PM
After Hours Top Gainers PT2 $STAK $ORIO $BRIA $CVKD $VIDA
0 · Reply
focafoca99
focafoca99 Jul. 17 at 8:52 PM
$CVKD communicated a CMO departure and a confidential separation agreement with Dr. Ferguson.
1 · Reply
BHWinehouse
BHWinehouse Jul. 17 at 1:25 PM
$CVKD Great drug, great CEO. This is VERY promising, but I'm not ready to jump back in yet...
1 · Reply
WallStreetSignals
WallStreetSignals Jul. 16 at 3:00 PM
$CVKD #CVKD Update: Advancing Innovation for Better Access to Care Cadrenal Therapeutics (#NASDAQ: #CVKD) is advancing novel therapies for life-threatening immune and thrombotic conditions, reflecting the broader principle that everyone deserves the opportunity to benefit from medical innovation and quality health care. Its lead candidate, **CAD-1005**, a first-in-class 12-LOX inhibitor, recently presented late-breaking Phase 2 data at the ISTH 2026 Congress, reporting a **greater than 25% reduction in thrombotic events** in patients with heparin-induced thrombocytopenia (HIT), a serious and potentially life-threatening condition. Continued research into treatments for underserved medical needs can help improve patient outcomes and support the goal of more equitable access to life-saving care. https://youtu.be/4UcqG2DwjEs
0 · Reply
MikeTechnician
MikeTechnician Jul. 15 at 5:32 PM
0 · Reply
MikeTechnician
MikeTechnician Jul. 15 at 5:04 PM
💊 $CVKD #NASDAQ Cadrenal Therapeutics Advances CAD-1005 Multi-Indication Strategy https://youtu.be/TXl0hf-BGNs?si=LyAaZGyIy5sl5EZt
0 · Reply